Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer
- Type
- Retraction
- Notice date
- 12/13/2023 0:00
- Journal
- Computational and Mathematical Methods in Medicine
- Publisher
- Hindawi
- Notice DOI
- 10.1155/2023/9868302
- Original paper DOI
- 10.1155/2022/7864114
Reasons
- Compromised Peer Review
- Investigation by Journal/Publisher
- Investigation by Third Party
- Paper Mill
- Unreliable Results and/or Conclusions